Elexacaftor-tezacaftor-ivacaftor (ETI) treatment improves Lung Clearance Index (LCI) in patients with Cystic Fibrosis (CF) independently from baseline respiratory function
F. Lucca (Verona, Italy), S. Volpi (Verona, Italy), R. Guarise (Verona, Italy), A. Borruso (Verona, Italy), M. Signorini (Verona, Italy), M. Cipolli (Verona, Italy)
Source: International Congress 2022 – Monitoring the effect of therapy with CFTR modulators
Session: Monitoring the effect of therapy with CFTR modulators
Session type: Oral Presentation
Number: 1622
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Lucca (Verona, Italy), S. Volpi (Verona, Italy), R. Guarise (Verona, Italy), A. Borruso (Verona, Italy), M. Signorini (Verona, Italy), M. Cipolli (Verona, Italy). Elexacaftor-tezacaftor-ivacaftor (ETI) treatment improves Lung Clearance Index (LCI) in patients with Cystic Fibrosis (CF) independently from baseline respiratory function. 1622
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|